Abbott, Nevro tout spinal cord stimulation tech

Abbott (NYSE:ABT) and Nevro (NYSE:NVRO) touted their spinal cord stimulation technologies at the annual North American Neurological Society meeting in Las Vegas. Two-year data from Abbott’s 42-patient Sunburst study revealed that a majority of patients chose its BurstDR therapy when given the choice during the long-term follow-up period and that stimulation from BurstDR provided pain relief through 24 months. Patient preference for Abbott’s BurstDR system grew over time, the company pointed out – 68% of patients chose BurstDR at 12 months compared to 81% at two years. “The BurstDR waveform is by far the most studied waveform in neurostimulation. It’s clear to the physicians we’re working with that Abbott is committed to ongoing research and real-world evidence,” Abbott’s medical director for neuromodulation, Dr. Allen Burton, said in prepared remarks. “This latest 24-month data continues to show strong consistent real-world outcomes with Abbott’s BurstDR, which is critical when physicians are making decisions for their patients,” Dr. Timothy Deer, president & CEO of the Spine and Nerve Center of the Virginias, added. Nevro presented data from three trials evaluating the safety and efficacy of its Senza HF10 neuromodulation therapy in patients dealing with chronic pain. In the company’s Senza-ULN trial, patients with chronic, intractable neck and/or upper limb pain experienced significant pain reduction after...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Neurological Neuromodulation/Neurostimulation Pain Management Wall Street Beat Abbott nevro Source Type: news